Astellas completes acquisition of Propella Therapeutics
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Advances Amgen's mission to serve patients with rare disease medicines
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
With an annual revenue of about $500 million, Spectrum will become part of the Industrial Solutions line of business within the Electronics & Industrial segment
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Subscribe To Our Newsletter & Stay Updated